Brief to Support Physician’s Ability to Provide Medication Abortion in Accordance with Evidence-based Guidance and Patient Need
The American Medical Women’s Association joins as a signatory on a merit stage amicus brief filed with the Supreme Court of the United States (SCOTUS) regarding the case of the Food and Drug Administration vs. Alliance for Hippocratic Medicine arguing in favor of the FDA approval of the use of mifepristone to end pregnancy through ten weeks gestation and to protect telehealth access to mifepristone. The brief was filed today and added to the SCOTUS docket.
This effort was led by Doctors for America (DFA) on behalf of the Reproductive Health Coalition, cofounded by AMWA and DFA.
The brief put forth four specific arguments::
- Mifepristone’s safety and effectiveness are rooted in sound scientific and clinical evidence;
- Mifepristone is a standard treatment option not only for abortion, but also for early pregnancy loss;
- The ready accessibility of mifepristone is essential to protect patient autonomy; and Continued judicial interference with FDA regulatory decision-making will undermine medical professionals’ trust in the judiciary.
- Continued judicial interference with FDA regulatory decision-making will undermine medical professionals’ trust in the judiciary.
As physicians, AMWA joins this legal position to advance the need for physicians to have the right to practice evidence-based medicine with the best interests of the patient at the forefront of every medical decision and to support patients right to access the care they need, including the most appropriate medication.
Both Doctors for America and AMWA, representing the RHC coalition, we believe the position of 5th circuit court of appeals got this case fundamentally and dangerously wrong, and threatens to undermine the FDA’s drug approval authority.The amicus brief incorporates devastating first-hand physician testimony on how restrictions to mifepristone have adversely impacted patients.
Our position is to urges the Supreme Court to put patients over politics and affirm the FDA’s approval of the use of mifepristone to end pregnancy through ten weeks gestation.
This amicus brief was filed by Columbia Law School’s Science, Health & Information Clinic, which provides pro bono legal assistance to DFA. Columbia Law student attorneys Angela Kang, Xingni (Cindy) Chen, and Priscilla Kim led work on the brief, with support from student attorneys Aniruddh Bakre, Nora Franco, Ryeaan Chaudhary, Stephanie Lim, and Zelly Rosa, SHIC Director Christopher Morten, and attorney Thomas Leatherbury.